List of Tepmetko drug patents

Tepmetko is owned by Emd Serono Inc.

Tepmetko contains Tepotinib Hydrochloride.

Tepmetko has a total of 8 drug patents out of which 0 drug patents have expired.

Tepmetko was authorised for market use on 03 February, 2021.

Tepmetko is available in tablet;oral dosage forms.

Tepmetko can be used as treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by administering an effective amount of tepotinib, treating a solid tumor, including lung cancer, having a met kinase alteration(s) by administering an effective amount of tepotinib.

Drug patent challenges can be filed against Tepmetko from February, 2025.

The generics of Tepmetko are possible to be released after 19 March, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8921357 EMD SERONO INC Pyridazinone derivatives
May, 2028

(5 years from now)

US8329692 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Oct, 2029

(6 years from now)

US8580781 EMD SERONO INC Pyridazinone derivatives
Mar, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284300 EMD SERONO INC Pyridazinone derivatives
Apr, 2028

(5 years from now)

US8658643 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Jul, 2028

(5 years from now)

US9062029 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Jul, 2028

(5 years from now)

US9403799 EMD SERONO INC Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase
Jul, 2028

(5 years from now)

US8927540 EMD SERONO INC Pyridazinone derivatives
Jul, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 3, 2026
Orphan Drug Exclusivity (ODE) Feb 3, 2028

Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 03 February, 2021

Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by administering an effective amount of tepotinib; Treating a solid tumor, including lung cancer, having a met kinase alteration(s) by administering an effective amount of tepotinib

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in